|
Orthopedic Surgery
A Phase 2B, Randomized, Multi-Center, Dose-Ranging, Study Assessing the Safety and Efficacy of PD 0348292 in the Prevention
of Venous Thromboembolic Events (VTE) in Subjects Undergiong and Elective, Unilateral Total Knee Replacement (Protocol A5571010)
Investigator: Bryan, William Jay
Phone Number: (713) 441-3476
A Phase 2B, Randomized, Multi-Center, Dose-Ranging, Study Assessing the Safety and Efficacy of PD 0348292 in the Prevention
of Venous Thromboembolic Events (VTE) in Subjects Undergiong and Elective, Unilateral Total Knee Replacement (Protocol A5571010)
Investigator: Muntz, James
Phone Number: (713) 795-5572
A Phase III, Randomised, Double Blind, Parallel-Group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg
bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial
Treatm
Investigator: Muntz, James
Phone Number: (713) 795-5572
CASSIOPEA (Clinical study Assessing SSR126517E Injections Once-weekly in Pulmonary Embolism therapeutic Approach) An international,
multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E
Investigator: Muntz, James
Phone Number: (713) 795-5572
Evaluation of the Factor Xa Inhibitor, PRT054021, Against Enoxaparin in a Randomized Trial for the Prevention of Venous Thromboembolic
Events After Unilateral Total Knee Replacement (EXPERT)
Investigator: Muntz, James
Phone Number: (713) 795-5572
International, multicenter, randomized parallel group, double-blind study, in patients with acute symptomatic deep vein thrombosis
of the lower limbs, demonstrating the bioequipotency at steady state of equimolar doses of SSR126517E (3.0mg) once a week
an
Investigator: Muntz, James
Phone Number: (713) 795-5572
|
